AzTrials
AzTrials

Kidney TransplantationNCT03045731

An US Mathematical Model in Predicting Renal Transplant Rejection

An observational study of Kidney Transplantation, run by Shanghai Zhongshan Hospital at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The purpose of this study is to establish an ultrasound mathematical model using acoustic radiation force impulse (ARFI) and contrast-enhanced ultrasonography (CEUS) for diagnosing the status of renal allografts. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Kidney Transplantation
How many people
180 participants
Where
1 siteChina
Study dates
Jan 2016to 31 Dec 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adults (over 18) who have undergone renal transplant for at Zhongshan Hospital.

Who may be able to join

  • Adults (over 18) who have undergone renal transplant at Zhongshan Hospital
  • Understanding the research situation
  • Signing informed consent voluntarily

Who cannot join

  • Urinary obstruction
  • Perirenal hematioma
  • Infection in operative sites

Trial locations and contacts

1 site in 1 country.

China1 site, 1 recruiting
  • Zhongshan Hospital

    Shanghai, Shanghai Municipality, 200032

    Jia Fan, fan.jia@zs-hospital.sh.cn

    Recruiting

Other trials in China

About this study

The purpose of this study is to establish an ultrasound mathematical model using acoustic radiation force impulse (ARFI) and contrast-enhanced ultrasonography (CEUS) for diagnosing the status of renal allografts.

Read the detailed description
  • There are various reasons for renal failure after kidney transplantation, such as delayed graft function (DGF) and acute rejection, acute renal tubular necrosis, chronic rejection and toxicity of immunosuppressive drugs. The diagnosis of renal allografts dysfunction can determine the direction of therapy. Currently, the gold standard of diagnosing renal allografts status is biopsies. However, biopsy has several drawbacks. It is invasive and can cause serious complications. These drawbacks urge investigators to find an accurate and non-invasive method to detect renal function. Elastography is a new way to detect tissue elasticity and can evaluate the tissue elasticity quantitatively. This method is proved to be of great value in diagnosing hepatic fibrosis (≥stage 2). Even though the investigation about this method is relatively less in allograft, the recent research shows that tissue elasticity does have relationship with pathological changes of transplanted kidney. Another new method, contrast-enhanced ultrasonography (CEUS), can indicate the blood perfusion of organ microcirculation. The accuracy rate of diagnosis of acute rejection(AR) can be 80% by using this method. It also has advantage in diagnosing acute tubular necrosis(ATN) and CAN. In addition, it produces no radioactive contamination as well as renal toxicity. This method has no serious side effect so it will not influence the normal function of patients' bodies and it can be performed for many times easily.
  • The research information about Elastography and CEUS is still at the primary stage. The value of one single parameter in diagnosing renal failure is restricted. So the establishment of an integrated mathematical model got by combining traditional methods (such as ultrasonography and color Doppler flow imaging) with these two new methods (Elastography and CEUS) is required to provide a systematical, multi-parameter diagnosis of allograft rejection.
  • What investigators have investigated before shows that different pathological changes of renal allograft can lead to regular changes in shear wave speed (SWS) and hemodynamics. By in-depth study of these changes, investigators aim to develop a mathematical model to diagnose the status of renal allograft.
  • To achieve this goal, the following things will be done:
  1. Investigators plan to enroll 100 renal transplant recipients .
  2. Before biopsy, these things will be done : a. Normal ultrasonography will be performed on transplanted kidney to measure their size, cortical thickness and vertebral body. b. Color Doppler flow imaging will be performed to see blood supply of transplanted kidney and resistive index (RI) of renal seg-mental will be measured. c. Contrast enhanced ultrasonography examination will be performed using Philips iU-22 ultrasonic apparatus with a C5-1 probe (Philips,Amsterdam, theNetherlands)with an intravenous bolus injection of 0.6-1.0mL SonoVue (Bracco, Milan, Italy). Area under curve (AUC), peak intensity (PI), time-to-peak (TTP), rise time (RT) and mean transit time (MTT) will be measured on central cortex of transplanted kidney. d. Elastography will be performed with a Siemens Acuson S2000 ultrasound machine using a 1- to 4-MHzcurved array multifrequency transducer (4 C1) (Siemens,Munich, Germany). Shear wave velocity (SWV) will be measured.
  3. Statistical analysis will be performed on the 10 quantitative parameters we got before (AUC, PI.etc ). The correlation between these parameters and condition of transplanted kidney (got by renal biopsy) will be evaluated. Then screening indexes will be optimized. On this basis, a mathematical model in diagnosing transplanted kidney is supposed to be built up.
  4. A ROC curve will be used to analyze the accuracy, sensitivity and specificity of this mathematical model.
  5. Then the US model will be verified in another 80 renal transplant recipients. Investigators will compare the diagnosis efficacy of transplanted kidney status got by the US model with the kidney biopsy result. Any parameter can be adjusted according to the verification results.
Keywords
kidney transplantation, ultrasound, mathematical model

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT03045731
Study groupRoleWhat they receive
Kidney transplant recipientsPatients who have received kidney transplantation in Zhongshan Hospital.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The diagnosis of the status of kidney allografts from biopsy results

    Measured: 3 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Feb 2017 (estimated)
  2. Study startJan 2016
  3. Primary completion30 Sep 2022 (estimated)
  4. Study completion31 Dec 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
180 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03045731
Sponsor's protocol ID
FDU-ZS-US-001
Status last verified
Mar 2021
First submitted
14 Jan 2017
Last updated
18 Mar 2021
Results posted
No

Publications

  • Williams WW, Taheri D, Tolkoff-Rubin N, Colvin RB. Clinical role of the renal transplant biopsy. Nat Rev Nephrol. 2012 Jan 10;8(2):110-21. doi: 10.1038/nrneph.2011.213.

    PubMed 22231130
  • Schwenger V, Keller T, Hofmann N, Hoffmann O, Sommerer C, Nahm AM, Morath C, Zeier M, Krumme B. Color Doppler indices of renal allografts depend on vascular stiffness of the transplant recipients. Am J Transplant. 2006 Nov;6(11):2721-4. doi: 10.1111/j.1600-6143.2006.01524.x.

    PubMed 17049059
  • Hanamura K, Tojo A, Kinugasa S, Asaba K, Fujita T. The resistive index is a marker of renal function, pathology, prognosis, and responsiveness to steroid therapy in chronic kidney disease patients. Int J Nephrol. 2012;2012:139565. doi: 10.1155/2012/139565. Epub 2012 Dec 16.

    PubMed 23304501
  • Benozzi L, Cappelli G, Granito M, Davoli D, Favali D, Montecchi MG, Grossi A, Torricelli P, Albertazzi A. Contrast-enhanced sonography in early kidney graft dysfunction. Transplant Proc. 2009 May;41(4):1214-5. doi: 10.1016/j.transproceed.2009.03.029.

    PubMed 19460520
  • Grzelak P, Szymczyk K, Strzelczyk J, Kurnatowska I, Sapieha M, Nowicki M, Stefanczyk L. Perfusion of kidney graft pyramids and cortex in contrast-enhanced ultrasonography in the determination of the cause of delayed graft function. Ann Transplant. 2011 Jan-Mar;16(1):48-53.

    PubMed 21436774
  • Schwenger V, Korosoglou G, Hinkel UP, Morath C, Hansen A, Sommerer C, Dikow R, Hardt S, Schmidt J, Kucherer H, Katus HA, Zeier M. Real-time contrast-enhanced sonography of renal transplant recipients predicts chronic allograft nephropathy. Am J Transplant. 2006 Mar;6(3):609-15. doi: 10.1111/j.1600-6143.2005.01224.x.

    PubMed 16468973
  • Fierbinteanu-Braticevici C, Andronescu D, Usvat R, Cretoiu D, Baicus C, Marinoschi G. Acoustic radiation force imaging sonoelastography for noninvasive staging of liver fibrosis. World J Gastroenterol. 2009 Nov 28;15(44):5525-32. doi: 10.3748/wjg.15.5525.

    PubMed 19938190
  • Arndt R, Schmidt S, Loddenkemper C, Grunbaum M, Zidek W, van der Giet M, Westhoff TH. Noninvasive evaluation of renal allograft fibrosis by transient elastography--a pilot study. Transpl Int. 2010 Sep;23(9):871-7. doi: 10.1111/j.1432-2277.2010.01057.x. Epub 2010 Feb 15.

    PubMed 20158692
  • Stock KF, Klein BS, Vo Cong MT, Sarkar O, Romisch M, Regenbogen C, Buttner M, Schuster T, Matevossian E, Amann K, Clevert DA, Heemann U, Kuchle C. ARFI-based tissue elasticity quantification in comparison to histology for the diagnosis of renal transplant fibrosis. Clin Hemorheol Microcirc. 2010;46(2-3):139-48. doi: 10.3233/CH-2010-1340.

    PubMed 21135489
  • Fischer T, Filimonow S, Rudolph J, Morgera S, Budde K, Slowinski T, Ebeling V, Taymoorian K, Giessing M, Thomas A. Arrival time parametric imaging: a new ultrasound technique for quantifying perfusion of kidney grafts. Ultraschall Med. 2008 Aug;29(4):418-23. doi: 10.1055/s-2006-927269. Epub 2007 Feb 21.

    PubMed 17315111
  • Schwenger V, Zeier M. Contrast-enhanced sonography as early diagnostic tool of chronic allograft nephropathy. Nephrol Dial Transplant. 2006 Oct;21(10):2694-6. doi: 10.1093/ndt/gfl449. Epub 2006 Jul 28. No abstract available.

    PubMed 16877483
  • Scholbach T, Girelli E, Scholbach J. Dynamic tissue perfusion measurement: a novel tool in follow-up of renal transplants. Transplantation. 2005 Jun 27;79(12):1711-6. doi: 10.1097/01.tp.0000164145.89275.02.

    PubMed 15973173

Questions about this trial

What is this clinical trial studying?

An observational study of Kidney Transplantation, run by Shanghai Zhongshan Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 18 Mar 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Wanyuan He, MD, PhD (0086-0-13916237059, he.wanyuan@zs-hospital.sh.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The diagnosis of the status of kidney allografts from biopsy results (time frame: 3 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03045731, which also lists 12 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Mar 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in